EPM editor Reece Armstrong sits down with Panna Sharma, CEO of Lantern Pharma to discuss what an Initial Public Offering of $27 million means for the company and where this biopharma is headed next.
Penny Pinnock, sales manager – Healthcare & Public Sector for Siemens Financial Services (SFS) discusses why NHS trusts must work together to meet the challenges facing their laboratories.
With the high costs of drug discovery, Tyler Golato, scientific lead at Molecule, discusses why new business models are needed if innovation is to continue.
Kathryn Moon, Life Science Risk & Insurance specialist at UK broker Gallagher, looks at why it can be essential for businesses in the industry to have a robust insurance policy in place to protect it.
Here, Mark Tempest, VWV partner in the Insolvency and Restructuring and Pharmaceuticals and Life Sciences teams, looks at the construction giant’s case in more detail and what pharma and life sciences should consider in order to protect themselves.
A new research paper has been released by Siemens Financial Services (SFS), describing ‘CFO 4.0’, which is the new breed of chief financial officer in the manufacturing industry that needs to drive and enable the digital transformation process.
The BIA and business intelligence group, Informa, have released their first quarterly financing update on the biotech sector, showing that venture capital financing and follow on financings on the public markets are off to a solid start
This year will be big for Duchenne muscular dystrophy (DMD) as interest in treatments is on the rise and deal activity is increasing, reported data and analytics company, GlobalData.
According to Catalyst Corporate Finance, UK service-based pharma businesses involved in ‘smart’ areas of the market are experiencing heightened interest from domestic and international acquirers.
Data and analytics company, GlobalData, has revealed its prediction that Merck will lead the way in licensing deals for the year when considering the success of the company since 2016.
Health systems are facing the biggest challenge in their existence: financial sustainability fuelled by the costs of prescription drugs. Here, Marisa Miraldo, associate professor at Imperial College Business School, goes into more detail…
